<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1642">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682548</url>
  </required_header>
  <id_info>
    <org_study_id>20-01799</org_study_id>
    <nct_id>NCT04682548</nct_id>
  </id_info>
  <brief_title>Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients</brief_title>
  <official_title>Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients With and Without Ocrelizumab Treatment, and Comparing Immune Responses to COVID-19 in MS Patients on Ocrelizumab and Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional, biospecimen collection study is designed to help us better&#xD;
      understand whether MS patients have impaired immune defenses to COVID-19 infection. The&#xD;
      potential influence of immune modulating medications for MS will be considered through these&#xD;
      exploratory studies. This study is also designed to provide context for interpretation of&#xD;
      anti-SARS CoV2 serologies in MS patients during convalescence from COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Seropositivie Rate Against SARS-CoV-2</measure>
    <time_frame>Baseline, Day 0</time_frame>
    <description>Seropositivity rate against SARS-CoV-2 (nucleocapsid and/or spike proteins, as available) as measured by the Roche DIA antibody assay in MS patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T Cell Response</measure>
    <time_frame>Baseline, Day 0</time_frame>
    <description>SARS-CoV-2 specific T cells will be measured using a well-validated assay such as ELISpot (enzyme-linked immune absorbent spot) to measure T cell responses to stimulation.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Covid19</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be obtained from participants.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Projected study size is 1000 MS patients for primary objective and additional 40&#xD;
        non-autoimmune COVID-19 convalescent control and 20 COVID-19 negative healthy controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (Part A and B):&#xD;
&#xD;
        ‚óè Patient is outside of infectious period of COVID-19 defined as follows:&#xD;
&#xD;
          -  Patient with mild to moderate illness who are not severely immunocompromised:&#xD;
&#xD;
               -  At least 10 days have passed since symptoms first appeared and&#xD;
&#xD;
               -  At least 24 hours have passed since last fever without the use of fever-reducing&#xD;
                  medications and&#xD;
&#xD;
               -  Symptoms (e.g. cough, shortness of breath) have improved&#xD;
&#xD;
          -  Patient with severe to critical illness or who are severely immunocompromised:&#xD;
&#xD;
               -  At least 10 days and up to 20 days have passed since symptoms first appeared&#xD;
&#xD;
               -  At least 24 hours have passed since last fever without the use of fever-reducing&#xD;
                  medications and&#xD;
&#xD;
               -  Symptoms (e.g. cough, shortness of breath) have improved&#xD;
&#xD;
                    -  Clinician-diagnosed MS treated or untreated with an approved DMT,&#xD;
&#xD;
                    -  Ages 18 to 60,&#xD;
&#xD;
                    -  EDSS 0 - 7,&#xD;
&#xD;
                    -  Able to give informed consent,&#xD;
&#xD;
                    -  Able to complete, or have someone help complete the patient questionnaire,&#xD;
&#xD;
                    -  No high dose steroids, or IVIG, or PLEX use within 3 months of blood sample,&#xD;
&#xD;
                    -  No convalescent plasma and/or polyclonal antibody treatments for COVID-19&#xD;
                       within 3 months of blood sample collection.&#xD;
&#xD;
        Inclusion Criteria (Part B only)&#xD;
&#xD;
          -  COVID-19 positive patients, who received OCR within 6 months of COVID 19 infection,&#xD;
&#xD;
          -  EDSS 0 - 6.&#xD;
&#xD;
        Exclusion Criteria (Part A and B):&#xD;
&#xD;
          -  Concurrent immunosuppressive therapy, active systemic cancer, primary or acquired&#xD;
             immunodeficiency (i.e., CVID, HIV infection),&#xD;
&#xD;
          -  Active drug or alcohol abuse,&#xD;
&#xD;
          -  Other anti-CD20 therapy apart from OCR,&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus,&#xD;
&#xD;
          -  End-organ failure (cardiac, pulmonary, renal, hepatic),&#xD;
&#xD;
          -  Systemic lupus erythematosus (SLE).&#xD;
&#xD;
        Exclusion Criteria (Part B only):&#xD;
&#xD;
          -  EDSS &gt;6,&#xD;
&#xD;
          -  Active infection (e.g., hepatitis).&#xD;
&#xD;
        Exclusion Criteria (Healthy Controls Sample)&#xD;
&#xD;
          -  Concurrent immunosuppressive therapy, active systemic cancer, primary or acquired&#xD;
             immunodeficiency (e.g. CVID, HIV infection),&#xD;
&#xD;
          -  Active ongoing drug or alcohol abuse,&#xD;
&#xD;
          -  Age &gt;60 or &lt;18,&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus,&#xD;
&#xD;
          -  End-organ failure (cardiac, pulmonary, renal, hepatic),&#xD;
&#xD;
          -  SLE&#xD;
&#xD;
          -  No high dose steroids, or intravenous immunoglobulin (IVIG) or plasma exchange (PLEX)&#xD;
             use within 3 months of blood sample collection,&#xD;
&#xD;
          -  No convalescent plasma and/or polyclonal antibody treatments for COVID-19 within 3&#xD;
             months of blood sample collection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilya Kister, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zoe Rimler</last_name>
    <phone>646-501-7511</phone>
    <email>zoe.rimler@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Ilya Kister, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Disease-Modifying Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

